PCI Biotech forms research collaboration with DCprime

OSLO: PCI  Biotech has  announced an  extensive research collaboration. Within the  collaboration,  DCprime  and  PCI  Biotech  will combine their know-how and technology  platforms  to  pursue  the  development  of novel cancer vaccination concepts based on tumour-independent antigens (TIAs).

PCI  Biotech  is  a  biopharmaceutical  late  stage clinical development company focusing  on  development  and  commercialisation  of  novel  therapies  for the treatment  of cancer through its  innovative photochemical internalisation (PCI) technology  platform. 

The company’s  lead  programme  fimaChem  consists  of  a pivotal study in bile duct cancer,  an  orphan  indication  with  a  high  unmet  need and without approved products.  fimaVacc applies  a unique  mode of  action to  enhance the essential cytotoxic  effect of  therapeutic cancer  vaccines, which  works in synergy with several  other state-of-the-art  vaccination technologies.  fimaNAc utilises the endosomal  release to provide  intracellular delivery of  nucleic acids, such as mRNA  and RNAi  therapeutics, thereby  addressing one  of the  major bottlenecks facing this emerging and promising field.


About the author

Leave a Reply

Your email address will not be published.